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Introduction: In our limited resection trial of pulmonary peripheral
ground-glass opacity (GGO) lesions from 1998 to 2002, limited
resection of Noguchi type A and B carcinomas seemed to have a
positive outcome. However, recently three of the 24 patients, with
mixed GGO lesions intraoperatively diagnosed as type B, developed
a solid lesion at the cut-end scar.
Methods: Medical records and radiology and pathology findings of
the three patients were reviewed. We also analyzed epidermal
growth factor receptor gene mutations when possible.
Results: Radiologically, these three second tumors were clearly
cut-end scar area recurrences. However, other pathologic and
mutation findings suggest metachronous primary cancers devel-
oped in Case 1, cut-end recurrence in Case 2, and needle biopsy
implantation in Case 3. It is difficult to definitively conclude
whether the second tumors were recurrences or metachronous
primaries.
Conclusions: These second tumors have convinced us that our
initial caution in concluding GGO lesions can be cured by limited
resection was very appropriate. The recurrences definitely indi-
cate that continuing follow-up attention for more than 5 years is
needed after limited resection even for GGO bronchioloalveolar
carcinomas.
Key Words: Lung, Bronchioloalveolar carcinoma, Pseudo-
papillary structure, Minimal invasion, Limited resection,
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From 1998 to 2002, we performed a limited resection trialof pulmonary ground-glass opacity (GGO) lesions 2 cm or
smaller identified by computed tomography (CT) in the lung
periphery, intraoperatively determining Noguchi’s adenocar-
cinoma classification1 by frozen section in 50 patients, which
protocol was approved by the institutional review board in
July 1998.2 Limited resection of Noguchi type A and B
carcinomas seemed to have a positive outcome. However,
recently three of the 24 patients, with GGO lesions intraop-
eratively diagnosed as Noguchi type B (localized bronchi-
oloalveolar carcinoma with a focus of collapse), developed a
solid lesion at the cut-end scar.
CASE 1
A 67-year-old, nonsmoking woman underwent right
upper lobe wedge resection for a 1.2 cm mixed GGO lesion
(Figure 1A), with the intraoperative pathologic diagnosis
of bronchioloalveolar carcinoma (BAC, type B) (Figures
2A–C). For the intraoperative frozen section evaluation,
the resected specimen margin was cut with scissors ex
vivo. The same evaluation process was also performed in
cases 2 and 3. Because of a positive cut end in the first
frozen section evaluation, she needed additional margin
resection, which resulted in a sufficient negative margin.
The final pathologic diagnosis was adenocarcinoma, mixed
subtype with predominant BAC component, and minimal
invasion (Figure 2D). The resection scar started to get
thicker 4.6 years after surgery and was judged tumorous 8
years after surgery (Figure 3). Although a positron emis-
sion tomography (PET) scan was negative, a broncho-
scopic biopsy found adenocarcinoma. She underwent right
upper lobectomy and lymph node dissection 8.7 years after
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the initial resection. Pathologically, there was an adeno-
carcinoma, mixed subtype with BAC, papillary, acinar and
poorly differentiated carcinoma components (Figures 4A–
C), T2N0M0, and an incidental BAC in atypical adenoma-
tous hyperplasia (AAH), T1N0M0. In the T2N0M0 tumor,
nuclear atypia were generally more severe than in the
initial GGO tumor. However, in the peripheral BAC areas,
the atypia was fairly mild, as is often observed in primary
lung adenocarcinomas (Figure 4D). No vessel invasion
was identified. Genetic analyses of the initial GGO lesion
found epidermal growth factor receptor (EGFR) gene mu-
tations L858R and S768I. However, the recurring T2N0M0
tumor and coincident T1N0M0 tumor had only the L858R
mutation. Interestingly, the AAH component in the
T1N0M0 tumor also had the L858R mutation.
CASE 2
A 63-year-old, nonsmoking woman underwent right
middle lobe wedge resection for a 1.1-cm mixed GGO
lesion (Figure 1B). The final pathologic diagnosis was
BAC with pseudopapillary structure strongly suggestive of
noninvasive cancer (type B; Figures 5A, B). A solid tumor
developed 5 years after surgery around the cut-end staples
(Figure 6). Because of a positive PET scan with fluorode-
oxyglucose accumulating only in the solid tumor, she
underwent right middle lobectomy and lymph node dissec-
tion 5.8 years after the initial resection. Pathologic diag-
nosis was an adenocarcinoma, mixed subtype with BAC,
papillary, acinar and solid components, T4(pm1)N2M0
with visceral pleura invasion and lymphatic permeation
(Figures 5C, D), despite negative PET-CT for intrapulmo-
nary and lymph node metastases. Genetic analyses showed
the EGFR mutations for the initial GGO lesion and the
recurring tumor were the same: E746-A750 del type 2.
CASE 3
Originally, a 70-year-old man underwent a CT-
guided percutaneous needle biopsy for a 2.0 cm mixed
GGO lesion in the right upper lobe (Figure 1C), which
FIGURE 1. High resolution com-
puted tomography (CT) scan be-
fore limited resection (arrows).
A, Case 1: 12-mm mixed ground-
glass lesion. B, Case 2: 11-mm
mixed ground-glass lesion. C, Case
3: Mostly pure ground-glass lesion,
20 mm in diameter.
FIGURE 2. The ground-glass opacity (GGO) lesion con-
sisted of (A) bronchioloalveolar carcinoma (BAC, 50%) and
collapse and (B) pseudopapillary structure with no invasive
components (50%), with (C) moderate nuclear atypia, and
(D) a few poorly differentiated carcinoma components (small
cancer nests). Final pathologic diagnosis was adenocarci-
noma, mixed subtype with predominant BAC component,
and minimal invasion, pT1NXM0, p0, ly-, v-.
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yielded highly atypical cuboidal cells suspected of adeno-
carcinoma. He underwent right upper lobe wedge resec-
tion, and the final pathologic diagnosis was adenocarci-
noma, mixed subtype with predominant BAC, papillary,
and apparent invasion (type C; Figures 7A–C). There were
also three AAHs in the resected specimen. After being
fully informed of the intraoperative underdiagnosis, poten-
tial outcomes, and potential additional treatment options,
he decided not to undergo additional treatment. After 8
years, a soft-part density area around the cut-end staples,
which we had diagnosed as a cut-end scar, suddenly grew,
accompanied by pleural effusion. We examined the effu-
sion and confirmed adenocarcinoma cells in it (Figure 7D).
We discussed treatment options with him, and, although he
had been a smoker, quitting smoking at the age of 45 years,
and genetic analyses showed no EGFR mutations in the
initial GGO lesion, we agreed on trying Gefitinb (Astra-
Zeneka, Osaka, Japan). The response was stable disease,
but after 5 months, he developed interstitial pneumonia.
He survived the interstitial pneumonia but died of lung
cancer 11 months after recurrence and 8.9 years after
limited resection. EGFR mutation analyses of the pleural
FIGURE 3. The resection scar as it
got thicker more than 4 years after
limited resection.
FIGURE 4. The tumor consisted of (A) bronchioloalveolar
carcinoma (BAC, 70%), (B) papillary component (15%), (C)
acinar component  poorly differentiated carcinoma com-
ponent (small cancer nests) (15%). D, In the peripheral BAC
areas, the atypia was fairly mild, as is often observed in pri-
mary lung adenocarcinomas. Final pathologic diagnosis was
adenocarcinoma, mixed subtype with BAC, papillary, acinar,
and solid components, pT2N0M0, p0, ly-, v-.
FIGURE 5. The ground-glass opacity (GGO) tumor con-
sisted of (A) bronchioloalveolar carcinoma (BAC, 50%), (B)
pseudopapillary structure strongly suggestive of noninvasive
cancer (50%) with severe nuclear atypia. Final pathologic
diagnosis was BAC with pseudopapillary growth pattern,
Noguchi type B, pT1NXM0, p0, ly-, v-. The second tumor
consisted of (C) papillary component (70%), (D) solid ade-
nocarcinoma component (10%), BAC (10%), and acinar
component (10%) and with severe cellular atypia. Final
pathologic diagnosis was adenocarcinoma, mixed subtype
with BAC, papillary, acinar, and solid components,
pT4(pm1)N2(#3, 4, 12)M0, p1, ly-, v.
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effusion adenocarcinoma cells failed to identify any mu-
tations.
COMMENTARY
Radiologically, these three second tumors were
clearly cut-end scar area recurrences, because they devel-
oped around the initial resection cut-end staples. We re-
viewed the pathology slides for Cases 1 and 2 and found
some components were similar between the initial GGO
lesion and the second tumor. However, the second tumors
also included components that were not found in the initial
GGO lesions. These tumors had EGFR gene mutations
common between the initial GGO and second tumors.
However, the Case 1 second tumor did not have the S768I
mutation of the initial GGO lesion. The Case 1 also
developed an incidental third BAC in an AAH, which is a
putative precursor for peripheral lung adenocarcinoma.3
What was more intriguing was that the BAC and AAH
components in the incidental third tumor also had the
L858R mutation but not the S768I mutation. The Case 3
initial resected specimen included three AAHs. There were
no clear patterns between the initial and recurrent tumors
at all.
Even though the trial was small, we reviewed the
backgrounds of the recurring patients versus the entire trial
for any differences. Not unexpectedly, we observed no pat-
terns at all.
These findings can be interpreted into two ways: the
second tumor was a cut-end recurrence, or the second
tumor was a metachronous primary cancer. If a cut-end
recurrence, it may have been due to cancer cells spreading
along the airway or vessels, jumping over or bypassing the
resection margin pathologically diagnosed as cancer free.
Tumor cell implantation around the cut ends may also have
been due to the positive margin in the first resection in
Case 1. In the Case 3, needle biopsy may have caused
tumor cell dissemination. However, we do not have addi-
tional clue, because we did not perform pleural lavage
cytology4 during initial resection of these cases. Better
margin evaluation methods are needed, and we are trying
lavage and cytologic examination, first reported by Hi-
gashiyama
et al.5,6
If they were a metachronous primary, it may have been
a result of field carcinogenesis.7 The fact in Case 1 that the
initial GGO cancer, second cancer, coincident third cancer,
and its AAH component shared the same EGFR mutation
L858R strongly suggests that they were metachronous pri-
mary tumors and a result of field carcinogenesis. It would
probably be beneficial to resect more lung parenchyma at the
initial resection, but there is no convincing evidence how
FIGURE 6. Around the cut-end
staples, a solid tumor developed 5
years after limited resection.
FIGURE 7. The ground-glass opacity (GGO) tumor con-
sisted of (A) bronchioloalveolar carcinoma (BAC) and (B)
partly pseudopapillary and (C) micropapillary components
with moderate cellular atypia. Final pathologic diagnosis was
adenocarcinoma, mixed subtype with predominant BAC,
and invasive components in the central area of the tumor,
which showed fibrotic changes or collapse of alveolar struc-
ture, Noguchi type C, pT1NXM0, p0, ly-, v-. (D) Adenocarci-
noma cells in pleural effusion: Overlapping cytologic fea-
tures, cluster of atypical cells with severe nuclear irregularity,
high N/C ratio, and cytoplasmic vacuoles.
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much is enough. Additionally, the patients noted increased
shortness of breath after the lobectomy compared with the
limited resection, so a successful limited resection has a
patient benefit.
Since Martini and Melamed8 described their criteria
for accepting multiple separate carcinomas as primary in
the lung in 1975, little has been added or modified despite
better understanding of tumor biology in the recent de-
cades. We still do not have an absolute standard for
differentiating multiple primary cancers from intrapulmo-
nary metastases. Although, in this multiinstitute investiga-
tion, we are still investigating the tumors in this report
genetically and may get more genetic information, we do
not think it will be much help in definitively concluding
whether the second tumors are cut-end recurrences or
metachronous primaries.
However, these second tumors have convinced
the author team that our initial caution in concluding GGO
lesions can be cured by limited resection was very appro-
priate. The recurrences definitely indicate that continuing
follow-up attention for more than 5 years is needed after
limited resection even for GGO BAC lesions. The ex-
tended follow-ups increase our experience and knowledge
bases. Without them, this report would not have occurred.
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